The Oxford study of Calcium channel Antagonism Cognition Mood instability and Sleep (OxCaMS): study protocol for a randomised controlled experimental medicine study

摘要

BackgroundThe discovery that voltage-gated calcium channel genes such as CACNA1C are part of the aetiology of psychiatric disorders has rekindled interest in the therapeutic potential of L-type calcium channel (LTCC) antagonists. These drugs, licensed to treat hypertension and angina, have previously been used in bipolar disorder, but without clear results. Neither is much known about the broader effects of these drugs on the brain and behaviour.